Portfolio

Make treatments safer, shorter, and more affordable and effective for all forms of leishmaniasis.
In the short term, better treatment regiments are being developed using existing drugs.
In the long term, the goal is to develop an entirely new generation of all-oral drugs.

The current portfolio for both visceral and cutaneous leishmaniasis includes:

	Discovery Aminopyrazoles CF series Daiichi Sankyo Hit-to-lead DNDI-5421 & DNDI-5610 Leishmaniasis Hit-to-lead Leishmaniasis L205 Series NTD Drug Discovery Booster Hit-to-lead Screening
	Translation CpG-D35 for CL DNDI-6148 DNDI-0690 DNDI-6174 GSK3186899/DDD853651 GSK3494245/DDD1305143
	Development Miltefosine + paramomycin combination (Africa) New CL combination New treatments for HIV/VL New treatments for PKDL New VL treatments (Latin America)
	Implementation SSG&PM (East Africa) New VL treatments (South Asia)

For more details on each project, see DNDi‘s Global Portfolio